** Drug developer Contineum Therapeutics' CTNM.O shares fall 2.5% to $12.74 in extended trading

** CTNM kicks off public offering of $75 million worth of shares

** Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets and William Blair are joint book-running managers for proposed offering

** Proceeds will be used to advance the development of its experimental drug, PIPE-791, and to fund research and development activities, among other purposes

** CTNM has 29.2 million outstanding shares for $365.4 million market cap, per LSEG data

** All seven brokerages covering the stock rate it "buy" or higher; median PT $22 — data compiled by LSEG

** As of last close, CTNM down 10.8% YTD

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com))